liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Rituximab for treatment of severe renal disease in ANCA associated vasculitis
Johns Hopkins University, Baltimore, MD, USA.
Charles University, Prague, Czech Republic .
Linköping University, Department of Medical and Health Sciences, Division of Drug Research. Linköping University, Faculty of Medicine and Health Sciences. Region Östergötland, Heart and Medicine Center, Department of Nephrology.
Hospital of the University of Pennsylvania, Philadelphia, USA.
Show others and affiliations
2016 (English)In: JN. Journal of Nephrology (Milano. 1992), ISSN 1121-8428, E-ISSN 1724-6059, Vol. 29, no 2, 195-201 p.Article in journal (Refereed) Published
Abstract [en]


Rituximab (RTX) is approved for remission induction in ANCA associated vasculitis (AAV). However, data on use of RTX in patients with severe renal disease is lacking.


We conducted a retrospective multi-center study to evaluate the efficacy and safety of RTX with glucocorticoids (GC) with and without use of concomitant cyclophosphamide (CYC) for remission induction in patients presenting with e GFR less than 20 ml/min/1.73 m2. We evaluated outcomes of remission at 6 months (6 M), renal recovery after acute dialysis at diagnosis, e-GFR rise at 6 M, patient and renal survival and adverse events.


A total 37 patients met the inclusion criteria. The median age was 61 years. (55–73), 62 % were males, 78 % had new diagnosis and 59 % were MPO ANCA positive. The median (IQR) e-GFR at diagnosis was 13 ml/min/1.73 m2 (7–16) and 15 required acute dialysis. Eleven (30 %) had alveolar hemorrhage. Twelve (32 %) received RTX with GC, 25 (68 %) received RTX with GC and CYC and seventeen (46 %) received plasma exchange. The median (IQR) follow up was 973 (200–1656) days. Thirty two of 33 patients (97 %) achieved remission at 6 M and 10 of 15 patients (67 %) requiring dialysis recovered renal function. The median prednisone dose at 6 M was 6 mg/day. The mean (SD) increase in e-GFR at 6 months was 14.5 (22) ml/min/m2. Twelve patients developed ESRD during follow up. There were 3 deaths in the first 6 months. When stratified by use of concomitant CYC, there were no differences in baseline e GFR, use of plasmapheresis, RTX dosing regimen or median follow up days between the groups. No differences in remission, renal recovery ESRD or death were observed.


This study of AAV patients with severe renal disease demonstrates that the outcomes appear equivalent when treated with RTX and GC with or without concomitant CYC.

Place, publisher, year, edition, pages
Springer, 2016. Vol. 29, no 2, 195-201 p.
Keyword [en]
Rituximab; Renal disease; ANCA vasculitis
National Category
Urology and Nephrology
URN: urn:nbn:se:liu:diva-124009DOI: 10.1007/s40620-015-0208-yISI: 000372244700008PubMedID: 25986390OAI: diva2:895040

Funding agencies:  National Center for Advancing Translational Sciences (NCATS) a component of the National Institutes of Health (NIH) [UL1 TR 001079]; NIH Roadmap for Medical Research

Available from: 2016-01-18 Created: 2016-01-18 Last updated: 2016-04-13Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Segelmark, MårtenEriksson, Per
By organisation
Division of Drug ResearchFaculty of Medicine and Health SciencesDepartment of NephrologyDivision of Neuro and Inflammation ScienceDepartment of Rheumatology
In the same journal
JN. Journal of Nephrology (Milano. 1992)
Urology and Nephrology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 84 hits
ReferencesLink to record
Permanent link

Direct link